Irish Residential REITs Stock News

ISE:GL9
ISE:GL9Food

Glanbia (ISE:GL9) One Off US$122.8M Loss Tests Bullish Growth Narrative

Glanbia (ISE:GL9) has reported its FY 2025 results with second half revenue of US$2.0 billion and basic EPS of US$0.34, alongside net income of US$83.9 million, putting fresh numbers behind the current share price of €17.25. The company has seen half year revenue move from US$2.02 billion with EPS of US$0.08 in 2024 H2 to US$1.93 billion and US$0.39 in 2025 H1, before landing at US$2.0 billion and US$0.34 in 2025 H2. This sets up a picture where margin trends and earnings quality are front of...
ISE:KRX
ISE:KRXBuilding

Assessing Kingspan Group’s (ISE:KRX) Valuation After Full-Year Earnings And Roofing Expansion

Why Kingspan Group’s latest earnings are on investors’ radar Kingspan Group (ISE:KRX) has attracted fresh attention after reporting full year 2025 earnings, with sales of €9,199 million and net income of €671.2 million, alongside progress in emissions reduction and US roofing expansion. See our latest analysis for Kingspan Group. The earnings release appears to have reset expectations, with the 1-day share price return of 7.72% lifting Kingspan to €85.8. A 30-day share price return of 18.92%...
ISE:IRES
ISE:IRESResidential REITs

European Small Caps With Insider Action Highlighting Undervalued Opportunities

As the pan-European STOXX Europe 600 Index reaches new heights, buoyed by an improving economic backdrop and marking its strongest yearly performance since 2021, investors are increasingly focusing on small-cap opportunities within this dynamic market landscape. In such a thriving environment, identifying stocks with strong fundamentals and insider activity can highlight potential undervalued opportunities in the European small-cap sector.
ISE:UPR
ISE:UPRHealthcare

Is Uniphar’s Rare-Disease Logistics Expansion with Zevra Reshaping the Investment Case for Uniphar (ISE:UPR)?

Zevra Therapeutics announced that it has entered into an exclusive expanded access distribution agreement with Ireland-based Uniphar, enabling Niemann-Pick Disease Type C patients in select territories outside Europe to obtain reimbursed named-patient supply of MIPLYFFA, the only approved therapy that targets the underlying pathology of this ultra-rare condition. The deal strengthens Uniphar’s position as a specialist partner for complex rare-disease logistics, highlighting its capabilities...